Fredag 27 December | 17:30:09 Europe / Stockholm
Svenska | English

SenzaGen

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-02-13 08:30 Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-16 - X-dag ordinarie utdelning SENZA 0.00 SEK
2024-05-15 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-02-14 - Bokslutskommuniké 2023
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning SENZA 0.00 SEK
2023-05-04 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning SENZA 0.00 SEK
2022-05-05 - Årsstämma
2022-02-11 - Bokslutskommuniké 2021
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning SENZA 0.00 SEK
2021-05-05 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-11 - X-dag ordinarie utdelning SENZA 0.00 SEK
2020-05-08 - Årsstämma
2020-02-13 - Bokslutskommuniké 2019
2019-12-18 - Extra Bolagsstämma 2019
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-16 - X-dag ordinarie utdelning SENZA 0.00 SEK
2019-05-15 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-09 - X-dag ordinarie utdelning SENZA 0.00 SEK
2018-05-08 - Årsstämma
2018-02-14 - Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Senzagen är verksamt inom medicinteknik. Bolaget utvecklar och genomför genomiska in vitro-tester, vilket innebär att olika kemikaliers toxikologiska förmåga inte testas på djur utan istället i provrör. Bolaget har utvecklat en teknologisk plattform som används för att studera substansers påverkan producerat av aktörer inom läkemedel, kosmetika- och kemikalieindustrin. Forskning och utveckling sker från huvudkontoret i Lund.
SenzaGen’s interim report January–March 2024: Breakeven in Q1 2024
2024-05-15 08:30:00

Message from the CEO
“SenzaGen has made history with a positive EBITDA for the first quarter 2024. I am incredibly proud and pleased with our growth and high gross margin, which have brought us to breakeven for the first time, a key step towards becoming a profitable growth company. The performance of our core platform GARD® was especially positive in the quarter, breaking sales records and growing by as much as 66% year-on-year. Our growing global customer base with high loyalty and several strong projects in development clearly show very exciting sales potential. Delivering strong sales combined with a high gross margin and effective cost controls will continue to be our highest priority.”

Peter Nählstedt, President and CEO

1 January–31 March 2024

  • Net sales totaled SEK 14.3 (12.3) million.
  • EBITDA amounted to SEK 0 (-1.8) million.
  • Earnings per share were SEK -0.13 (-0.20).
  • Cash and cash equivalents at 31 March amounted to SEK 12.5 (31.7) million.

Important events in the quarter

  • SenzaGen’s orders received from the chemicals industry continued to increase with two follow-on orders from the same customer for GARD®skin tests worth SEK 1.5 million and SEK 0.8 million, respectively.
  • SenzaGen presented the results of its partnership with L’Oréal at the largest toxicology event in the world, the SOT Annual Meeting and ToxExpo in the US. This partnership serves as an important point of reference for the toxicology industry.

Livestream presentation
SenzaGen is pleased to invite press and investors to a livestream presentation at 9:00 on May 15. The presentation will be given by SenzaGen’s President and CEO Peter Nählstedt, followed by a Q&A session moderated by Carnegie Investment Bank’s analyst Klas Palin. The presentation will be held in Swedish.

Time: Wednesday May 15, 9:00–10:00 CEST.
Link to the livestream: https://youtube.com/live/kh3swMMDJPI?feature=share

The presentation can be watched afterwards at SenzaGen’s website: https://senzagen.com/investors/presentations/

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Mobile: +46 700 23 44 31

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Mobile: +46 708 20 29 44

About us

SenzaGen is a corporate group that aims to be a leader in in vitro science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser. 

This information is information that SenzaGen is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-05-15 08:30 CEST.

Attachments

SenzaGen AB (publ) Interim Report January–March 2024

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden